These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28654672)

  • 21. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
    Mercadante S; Masedu F; Valenti M; Aielli F
    Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.
    Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS
    BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are there cost benefits to fentanyl for breakthrough pain?
    Davis MP
    J Pain Symptom Manage; 2012 Sep; 44(3):e1-2. PubMed ID: 22939453
    [No Abstract]   [Full Text] [Related]  

  • 25. Fentanyl for breakthrough cancer pain: where are we?
    Meriggi F; Zaniboni A
    Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
    Husic S; Imamovic S; Matic S; Sukalo A
    Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacoeconomics of breakthrough cancer pain.
    Kuo KL; Saokaew S; Stenehjem DD
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
    Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
    J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
    Zucco F; Bonezzi C; Fornasari D
    Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
    Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
    J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
    Jandhyala R; Fullarton J
    BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
    Mercadante S; Marchetti P; Cuomo A; Mammucari M; Caraceni A;
    Support Care Cancer; 2016 Feb; 24(2):961-968. PubMed ID: 26438145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
    Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
    Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
    Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
    Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review.
    Mercadante S
    Crit Rev Oncol Hematol; 2018 Feb; 122():60-63. PubMed ID: 29458790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
    Lux EA; Schwittay A; Kleeberg UR; Papke J
    MMW Fortschr Med; 2018 Jul; 160(Suppl 4):18-23. PubMed ID: 29974433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.